OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bazhenova on the FDA Approval of Sunvozertinib for EGFR-Mutated mNSCLC

July 2nd 2025

Lyudmila A. Bazhenova, MD, discusses ways that sunvozertinib expands the treatment paradigm for EGFR-mutated metastatic non–small cell lung cancer.

Dr Riechelmann on the Management of Refractory Carcinoid Syndrome in Functional GI NETs

July 2nd 2025

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.

Dr Raza on Early Safety and Efficacy Data With NXC-201 in AL Amyloidosis

July 1st 2025

Shahzad Raza, MD, shares preliminary data from the NEXICART-2 trial of NXC-201 in relapsed/refractory light chain amyloidosis.

Dr Kelly on Final OS and Long-Term DFS Benefit With Adjuvant Nivolumab After CRT in GEJ Cancer

July 1st 2025

Ronan J. Kelly, MD, expanded on data from the phase 3 CheckMate 577 study of adjuvant nivolumab following CRT in resected esophageal and GEJ cancer.

Dr Jani on the Inclusion of PRO End Points in Lung Cancer Clinical Trials

July 1st 2025

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

Dr Uppaluri on the Implications of the FDA Approval of Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

July 1st 2025

Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.

Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer

July 1st 2025

Bhavana Pothuri, MD, discusses remaining unmet needs for patients with recurrent/advanced endometrial cancer.

Dr Vasquez on the Rationale for Investigating NAMPT Inhibition in Rhabdomyosarcoma

June 30th 2025

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

Dr Mascarenhas on the Safety of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis

June 30th 2025

John O. Mascarenhas, MD, discusses the safety profile of imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.

Dr Thaker on the Safety of IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer

June 30th 2025

Premal H. Thaker, MD, MS, discusses the safety of intraperitoneal administration of IMNN-001 plus neoadjuvant chemotherapy in epithelial ovarian cancer.

Dr Soror on Patient-Reported Outcomes in Hospitalized Patients With Cancer

June 30th 2025

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

Dr Ansley on Inavolisib Plus Palbociclib/Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

June 30th 2025

Katherine C. Ansley, MD, discusses the importance of the phase 3 INAVO120 trial in PIK3CA-mutated, hormone receptor–positive, HER2-negative breast cancer.

Dr Huang on the Efficacy of Sintilimab Plus Chidamide and P-GemOx in Treatment-Naive ENKTL.

June 30th 2025

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Dr Wainberg on Phase 2 Domvanalimab/Zimberelimab/Chemo Data in Gastric Cancer

June 30th 2025

Zev A. Wainberg, MD, MSc, discusses data from the EDGE-Gastric trial of domvanalimab plus zimberelimab and FOLFOX in first-line, metastatic gastric cancer.

Dr Arora on Findings From a SEER Database Analysis in Mantle Cell Lymphoma

June 30th 2025

Ruby Arora, MD, discusses findings from a SEER database analysis of mantle cell lymphoma incidence rates from 2000 to 2021.

Dr Scarfò on the Rationale for Evaluating BGB-16673 in Relapsed/Refractory CLL

June 30th 2025

Lydia Scarfò, MD, explains the rationale for evaluating the BTK degrader BGB-16673 for patients with relapsed/refractory CLL.

Dr Mouabbi on Developing Consensus Around Treatment De-Escalation in HER2+ Breast Cancer Following pCR

June 27th 2025

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

Dr Danilov on the Evolution of Chemotherapy-Free Treatment Options in MCL

June 27th 2025

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Dr El-Saghir on the Implications of the RIGHT Choice Trial of Ribociclib Plus ET in HR+, HER2– Advanced Breast Cancer

June 27th 2025

Nagi S. El-Saghir, MD, FACP, FASCO, discusses the clinical implications of the phase 2 RIGHT Choice trial.

Dr Shitara on the Unique Mechanisms of Action of Domvanalimab Plus Zimberelimab in GI Cancer

June 27th 2025

Kohei Shitara, MD, details the mechanisms of action of the investigational therapies domvanalimab and zimberelimab for gastrointestinal cancer.